Harness the Power of Glo for Cancer Research CellTiter-Glo

Harness the Power of Glo for Cancer Research
CellTiter-Glo® Luminescent Cell Viability Assay
Determine viable cell number through
bioluminescent quantitation of the viablity
biomarker, ATP.
• Sensitive: Detect as few as 10 cells in 384well format; 50 cells in 96-well format.
• Simple: Homogeneous add-mix-measure
assay. No cell washing or removal of
culture media.
• Fast: Data can be recorded 10 minutes
after reagent addition.
• Robust: Stable luminescent signal with
half-life generally >5 hours.
CytoTox-Glo™ Cytotoxicity Assay
Determine cytotoxicity through loss of membrane
integrity with the cytotoxicity biomarker,
“dead cell” protease.
• Sensitive: Detect as little as a 2-5%
decrease in viable cell number in a
population of 10,000 cells.
• Simple: Homogeneous add-mix-measure
assay. No cell washing or removal of
culture media.
• Fast: Data can be recorded 15 minutes
after reagent addition.
• Flexible: Determine total cells per well with
optional total cell lysis protocol. Cell lysis
reagents included.
mediators of
cancer cell
with sensitive
Harness the Power of Glo for Cancer Research
Ordering Information
CellTiter-Glo® Luminescent Cell Viability Assay
CytoTox-Glo™ Cytotoxicity Assay
Fisher Cat. #
10 x 10ml
10 x 100ml
5 x 10ml
2 x 50ml
CellTiter-Glo® Luminescent Cell Viability Assay contains CellTiter-Glo Substrate and CellTiter-Glo Buffer. Mixing of the CellTiter-Glo Substrate with the CellTiter-Glo Buffer
creates the CellTiter-Glo Reagent. Each milliliter of CellTiter-GloReagent give 10 x 100µl assays in a 96-well plate or 40 x 25µl assays in a 384-well plate.
CytoTox-Glo™ Cytotoxicity Assay contains AAF-Glo™ Substrate, Luciferin Detection Reagent, Luminescent Assay Buffer and Digitonin. Mixing of the AAF-Glo Substrate with
Luciferin Detection Reagent creates the CytoTox-Glo Reagent. Each milliliter of CytoTox-Glo Reagent give 20 x 50µl assays in a 96-well plate or 80 x 12.5µl assays in a 384well plate. Sufficient buffer and digitonin supplied to treat every well for total cell luminescence following dead cell luminescence determination.
CytoTox-Glo and AAF-Glo are trademarks and CellTiter-Glo is a registered trademarks of Promega Corporation. Product may be covered by issued or pending patents. Please
visit www.promega.com for more information.
Recent citations for the CellTiter-Glo Assay in cancer research
Bakkar, N., et al. (2008) IKK/NF-κB regulates skeletal myogenesis
via a signaling switch to inhibit differentiation and promote
mitochondrial biogenesis. J. Cell Biol. 180, 787-802.
Beitzinger, M., et al. (2008) p73 poses a barrier to malignant
transformation by limiting anchorage-independent growth. EMBO J.
in press.
Dedieu, S., et al. (2008) LRP-1 silencing prevents malignant cell
invasion despite increased pericellular proteolytic activities. Mol.
Cell. Biol. In press.
Dip, R., et al. (2008) Global gene expression profiles induced by
phytoestrogens in human breast cancer cells. Endocr. Relat. Cancer
15, 161-73.
Holm, R., et al. (2008) Expression of ZNF652, a novel zinc finger
protein, in vulvar carcinomas and its relation to prognosis. J. Clin.
Pathol. 61, 59-63.
Lin, W.M., et al. (2008) Modeling genomic diversity and tumor
dependency in malignant melanoma. Cancer Res. 68, 664-73.
Liu, Y.-Y., et al. (2008) A role for ceramide in driving cancer cell
resistance to doxorubicin. FASEB J. in press.
Pühler, F. et al. (2008) Generation of a recombinant oncolytic
Newcastle disease virus and expression of a full IgG antibody from
two transgenes. Gene Therapy 15, 371-83.
Tsai, J., et al. (2008) Discovery of a selective inhibitor of oncogenic
B-Raf kinase with potent antimelanoma activity. PNAS 105, 3041-6.
Yaba, A., et al. (2008) A putative mitotoic checkpoint dependent on
mTOR function controls cell proliferation and survival in ovarian
granulosa cells. Reproductive Sciences 15, 128-38
Zhdanov, A.V., et al. (2008) Dynamics of intracellular oxygen in
PC12 cells upon stimulation of neurotransmission. J. Biol. Chem.
283, 5650-61.